THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINAL PLANT & BOTANICAL REFERENCE PROFILE CODE: [BOT-18] ID: TIP-MED-000597

Punarnava (Boerhavia diffusa)

Active Ingredient / Scientific Identity: Boerhavia diffusa L. • Class: Pharmacognosy & Phytochemistry • Nyctaginaceae (Dried Whole Creeping Herb and Root)

⚖️ Compare 579 Drugs
THE INDIAN PHARMACIST — Educational Reference Sheet
Profile: Punarnava (Boerhavia diffusa) ([BOT-18] | ID: TIP-MED-000597) • Last Reviewed: 2026-11-10
Source URL: https://theindianpharmacist.com/medicine/bot-18-punarnava/
Generic / Entity NamePunarnava (Boerhavia diffusa) ([BOT-18])
Verified Indian Brands / RefStandardised Pharmacopoeial Crude Drug / Extract (IP / API Reference)
Pharmacological ClassPharmacognosy & Phytochemistry • Nyctaginaceae (Dried Whole Creeping Herb and Root)
Available Dosage FormsOfficial Plant Part: Dried Whole Creeping Herb and Root | Marker Compounds: Rotenoid isoflavonoids (Boeravinon
Regulatory ClassificationClassical ASU Botanical (API Part I Vol I) and Indian Pharmacopoeia Herbal Monograph.
Key Warning & Review DateNaturally high potassium salt content in crude root extracts poses hyperkalaemia risk in Stage 4–5 Chronic Kidney Disease (CK
Reviewed: 2026-11-10
Safety Matrix:⚖️ Regulatory Framework: Classical ASU Botanical (API Part I Vol I) and India✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Punarnava (Boerhavia diffusa) (TIP-MED-000597, Reference Code [BOT-18]) is classified under Medicinal Plants, Botanicals & Phytopharmaceuticals as a Pharmacognosy & Phytochemistry • Nyctaginaceae (Dried Whole Creeping Herb and Root). Within the Indian regulatory and compendial framework, it is governed under Classical ASU Botanical (API Part I Vol I) and Indian Pharmacopoeia Herbal Monograph..

Verified Indian Market Examples / Compendial Status:
Standardised Pharmacopoeial Crude Drug / Extract (IP / API Reference)
Botanical Standardisation Note: Authenticate by macroscopic, microscopic, and HPTLC/HPLC marker assay (Rotenoid isoflavonoids (Boeravinones A–J), quinolizidine alkaloid Punarnavine, and potassium nitrate salts) per Indian Pharmacopoeia (IP) and Ayurvedic Pharmacopoeia of India (API).
Dosage Forms & Available Strengths:
Official Plant Part: Dried Whole Creeping Herb and Root | Marker Compounds: Rotenoid isoflavonoids (Boeravinones A–J), quinolizidine alkaloid Punarnavine, and potassium nitrate salts
Routes: Oral / Topical as specified by classical API or standardized extract monograph

Pharmacognosy, Phytochemistry & Botanical Standardisation

Accepted Botanical Binomial & Authority: Boerhavia diffusa L.

Botanical Family: Nyctaginaceae

Official Authenticated Plant Part: Dried Whole Creeping Herb and Root

Major Phytochemical Constituents & IP/API Marker Compounds: Rotenoid isoflavonoids (Boeravinones A–J), quinolizidine alkaloid Punarnavine, and potassium nitrate salts

Punarnava (Boerhavia diffusa) Botanical Reference Illustration

Traditional / Classical Ayurvedic Context: Classical Ayurvedic Mutrala (mild diuretic) and Shothahara herb (Punarnavadi Mandura / Punarnavasava).

Modern Clinical Evidence Assessment (Clearly Distinguished from Traditional Use): Preclinical and traditional use as a mild potassium-rich diuretic and hepatoprotective adjunct; MUST NOT replace loop diuretics or disease-modifying heart/renal failure therapy in clinical oedema.

Quality Control, Adulteration & Contaminant Limits: Authenticate via HPTLC/HPLC marker assay; screen for heavy metals (Lead <=10 ppm, Arsenic <=3 ppm, Cadmium <=0.3 ppm, Mercury <=1 ppm), microbial load, and aflatoxins B1/B2/G1/G2 per IP/API.

Indian Regulatory Classification (ASU vs Phytopharmaceutical vs FSSAI): Classical ASU Botanical (API Part I Vol I) and Indian Pharmacopoeia Herbal Monograph.

3. Mechanism of Action & Pharmacodynamics

Major Phytochemical Constituents & Pharmacological Actions: Rotenoid isoflavonoids (Boeravinones A–J), quinolizidine alkaloid Punarnavine, and potassium nitrate salts. Preclinical and traditional use as a mild potassium-rich diuretic and hepatoprotective adjunct; MUST NOT replace loop diuretics or disease-modifying heart/renal failure therapy in clinical oedema.

4. Therapeutic Indications & Evidence-Supported Uses

  • Traditional / Classical Context: Classical Ayurvedic Mutrala (mild diuretic) and Shothahara herb (Punarnavadi Mandura / Punarnavasava).
  • Modern Clinical Evidence Assessment: Preclinical and traditional use as a mild potassium-rich diuretic and hepatoprotective adjunct; MUST NOT replace loop diuretics or disease-modifying heart/renal failure therapy in clinical oedema.

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Pharmacognostic & Clinical Evidence Summary: Preclinical and traditional use as a mild potassium-rich diuretic and hepatoprotective adjunct; MUST NOT replace loop diuretics or disease-modifying heart/renal failure therapy in clinical oedema.

Administration & Meal Timing: Authenticated Plant Part Used: Dried Whole Creeping Herb and Root. Naturally high potassium salt content in crude root extracts poses hyperkalaemia risk in Stage 4–5 Chronic Kidney Disease (CKD) or patients taking ACE inhibitors, ARBs, or spironolactone!

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Complex multicomponent phytoconstituent disposition involving intestinal deglycosylation by gut microbiota, hepatic Phase II glucuronidation/sulfation, and potential modulation of CYP450 and P-gp efflux pumps.
Metabolism & Biotransformation:
Intestinal microbial hydrolysis and hepatic Phase I/II biotransformation of secondary metabolites.
Elimination & Renal Adjustment:
Avoid unstandardised herbal extracts in Stage 3–5 Chronic Kidney Disease (risk of hyperkalaemia or nephrotoxic adulterants).
Hepatic Impairment Considerations:
Avoid high-dose concentrated botanical extracts in pre-existing hepatic disease; discontinue immediately if jaundice or transaminase elevation occurs.

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Hypersensitivity to Boerhavia diffusa L. or other members of the Nyctaginaceae family
  • Naturally high potassium salt content in crude root extracts poses hyperkalaemia risk in Stage 4–5 Chronic Kidney Disease (CKD) or patients taking ACE inhibitors, ARBs, or spironolactone!

Key Clinical Precautions: Naturally high potassium salt content in crude root extracts poses hyperkalaemia risk in Stage 4–5 Chronic Kidney Disease (CKD) or patients taking ACE inhibitors, ARBs, or spironolactone!

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Naturally high potassium salt content in crude root extracts poses hyperkalaemia risk in Stage 4–5 Chronic Kidney Disease (CKD) or patients taking ACE inhibitors, ARBs, or spironolactone!
Serious / Dose-Limiting Adverse Effects:
  • Naturally high potassium salt content in crude root extracts poses hyperkalaemia risk in Stage 4–5 Chronic Kidney Disease (CKD) or patients taking ACE inhibitors, ARBs, or spironolactone!

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Naturally high potassium salt content in crude root extracts poses hyperkalaemia risk in Stage 4–5 Chronic Kidney Disease (CKD) or patients taking ACE inhibitors, ARBs, or spironolactone!

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Verify botanical binomial authenticity (exclude adulterants/substitutes), HPTLC marker content, heavy metal limits (Pb, As, Cd, Hg), aflatoxins, and pesticide residues per IP/API standards.

Pharmacist Patient Counselling Points:

  • Natural or herbal origin does NOT automatically mean risk-free; always disclose botanical supplements to your doctor and pharmacist.
  • Naturally high potassium salt content in crude root extracts poses hyperkalaemia risk in Stage 4–5 Chronic Kidney Disease (CKD) or patients taking ACE inhibitors, ARBs, or spironolactone!
  • Never discontinue prescribed allopathic chronic disease medicines (antihypertensives, antidiabetics, anticonvulsants, or antivirals) in favour of unverified herbal products.

Storage, Stability & Dispensing Safeguards: Store dried botanical material and extracts in airtight, light-resistant containers below 25°C protected from humidity and fungal/aflatoxin contamination.

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP — Herbs and Herbal Products Addendum); Ayurvedic Pharmacopoeia of India (API — Ministry of AYUSH); CDSCO Rule 122E Phytopharmaceutical Drug Guidelines.

Official Verification Portals: Ministry of AYUSH — Pharmacopoeia Commission for Indian Medicine & Homoeopathy (PCIM&H) • Indian Pharmacopoeia Commission (IPC) — Herbal Monographs • CDSCO — Drugs and Cosmetics Rules (ASU & Phytopharmaceuticals)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

← Back to All 644 Reference Profiles 📖 Explore 40 Knowledge Hub Articles → ✉️ Report Errata / Feedback
Educational Reference Notice: This printout from THE INDIAN PHARMACIST (https://theindianpharmacist.com/medicine/bot-18-punarnava/, Last Reviewed: 2026-11-10) is an educational reference sheet for students and healthcare learners. It is NOT an official prescribing guideline or patient-specific treatment order.